Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.
After losing two jury trials, Johnson & Johnson/DePuy can now celebrate the fact that a jury has ruled in its favor regarding the company's ASR all metal hip implant.
Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.
As if 8,000-plus lawsuits alleging faulty all metal helps weren't enough, Johnson & Johnson/DePuy data from an Illinois hospital suggests that repeat surgeries for patients dealing with the implants keep rising.
A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.
When Johnson & Johnson's metal-on-metal hip implants failed an internal safety test, the company opted against fixing the issue and instead just changed its protocols, a witness testified in one of thousands of lawsuits the drug and device giant now faces.
Johnson & Johnson was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled.
Three plaintiffs settled their lawsuits against Johnson & Johnson ($JNJ)/DePuy over health problems they say stemmed from the failure of the company's metal-on-metal hip implants.
Yet another patient is suing Johnson & Johnson ($JNJ) for health problems he says were caused by one of the company's metal-on-metal hip implants, adding to the thousands of lawsuits filed previously in the matter.
Get used to the name "Pinnacle." Johnson & Johnson ($JNJ) has a metal-on-metal hip system with the name poised to deliver an onslaught of legal problems to the company. Even more, as Reuters reports, observers believe the growing controversy could surpass J&J legal and financial costs in the wake of its massive recall of a predecessor product two years ago.